CCM
MED icon

Chimera Capital Management’s Medifast MED Stock Holding History

Chimera Capital Management’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-88,597
Closed -$9.6M – 235
2022
Q3 		$9.6M Buy
+88,597
New +$12.7M 2.67% 5

Other funds holding MED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Chimera Capital Management's MED Position: Q4 2022 in Review

Chimera Capital Management sold out of Medifast (MED) in Q4 2022, closing a stake of 88,597 shares — an estimated $9.6M sold.

Chimera Capital Management first reported a position in MED in Q3 2022 and held it in 1 quarter. The position peaked at $9.6M in Q3 2022. 279 funds tracked by Wall St. Rank hold MED as of Q4 2022.

  • Chimera Capital Management reported no remaining Medifast position as of Q4 2022 after selling out during the quarter.
  • Chimera Capital Management sold 88,597 Medifast shares in Q4 2022, an estimated $9.6M.
  • Chimera Capital Management first reported a position in Medifast in Q3 2022 and held it in 1 quarter.
  • Chimera Capital Management's Medifast position peaked at $9.6M in Q3 2022.
  • 279 funds tracked by Wall St. Rank held Medifast as of Q4 2022.

Based on Chimera Capital Management's 13F filing for Q4 2022, filed 15 Feb 2023.